DDP225 is an oral noradrenaline reuptake inhibitor (NARI) and a weak 5HT3 receptor antagonist that Dynogen is developing for IBS-d. Noradrenaline and serotonin are neurotransmitters that are known to be involved in the control of the gastrointestinal system. The unique combination of noradrenaline reuptake inhibition and weak 5HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d, enabling efficacy to be achieved at very low and well tolerated doses of DDP225. Dynogen licensed preclinical and clinical data related to DDP225 from Mitsubishi Tanabe Pharma in October 2003. It has been dosed to over 450 human subjects for durations up to 12 weeks, and at single doses up to 100 mg. Dynogen owns issued patents and pending patent applications related to the use of DDP225 as a treatment for IBS.
Post Edited By Moderator (Admin) : 3/10/2008 10:39:44 AM (GMT-6)